The α3β4 nicotinic acetylcholine receptor (nAChR) is a potential therapeutic target for the treatment of drug dependence and addiction, lung cancer, overeating and obesity and other disorders.
α-Conotoxin analogue [S9K]TxID, obtained based on the modification of TxID, exhibited an IC
